Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments Corp has demonstrated a significant upward trajectory in its Medicare Advantage membership, achieving a remarkable 53% growth during the recent annual enrollment period, which positions the company well with approximately 153,000 members for the 2026 plan year. Furthermore, Clover's expectations for enhanced new member revenue, projected to exceed $70 per member per month, and the anticipated benefits of being recognized as a 4-star plan in 2026 suggest a robust improvement in contribution margins, driven by improved health documentation and higher retention rates. Finally, the company's strategic focus on adopting its proprietary Clover Assistant technology continues to enhance medical cost ratios, ultimately contributing to better unit economics and margin contributions as these new cohorts mature through 2027 and beyond.

Bears say

Clover Health Investments Corp is facing a negative outlook primarily due to the projected decline in gross profit margins, which is anticipated as a result of absorbing new members with lower profitability. The company's inability to retain a 4-Star rating has raised concerns about potential impacts on future Medical Loss Ratios (MLR) and earnings, which could lead to negative revisions in consensus forecasts. Additionally, various risks such as regulatory changes, adverse-selection due to market exits by larger peers, and increased competition in the Medicare Advantage space contribute to uncertainties in Clover's financial outlook.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.